$158.46 -4.3 -2.6%
Last Trade - 26/02/21
| Market Cap | £298.98bn |
| Enterprise Value | £306.22bn |
| Revenue | £59.28bn |
| Position in Universe | 17th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 03rd Jan | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 71,890 | 76,450 | 81,581 | 82,059 | 82,584 | 82,584 | 88,863 | 93,398 | +2.8% | ||
| +25.8 | -2.5 | +11.1 | +13.7 | -9.0 | +2.2 | +23.1 | +8.87 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
| Last Annual | January 3rd, 2021 |
| Last Interim | January 3rd, 2021 |
| Incorporated | November 10, 1887 |
| Public Since | September 25, 1944 |
| No. of Shareholders: | 132,376 |
| No. of Employees: | 134,500 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Dow Jones Composite , Dow Jones Industrial Average , FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 2,628,679,824 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Johnson And Johnson Plz, NEW BRUNSWICK, 08933-0001, United States |
| Web | https://www.jnj.com/ |
| Phone | +1 732 5242455 |
| Contact | Christopher DelOrefice (Vice President, Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 26/02/21, shares in Johnson & Johnson are trading at $158.46, giving the company a market capitalisation of £298.98bn. This share price information is delayed by 15 minutes.
Shares in Johnson & Johnson are currently trading at $158.46 and the price has moved by 13.9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Johnson & Johnson price has moved by -12.13% over the past year.
Of the analysts with advisory recommendations for Johnson & Johnson, there are there are currently 6 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Johnson & Johnson is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Johnson & Johnson is scheduled to issue upcoming financial results on the following dates:
The Johnson & Johnson dividend yield is 2.51% based on the trailing twelve month period.
Last year, Johnson & Johnson paid a total dividend of 3.98, and it currently has a trailing dividend yield of 2.51%. Looking ahead, Johnson & Johnson has not announced an ex-dividend date yet and the next dividend pay date is 2021-03-09.
Johnson & Johnson has yet to annouce their ex-dividend date and the next dividend pay date is 2021-03-09. The historic dividend yield on Johnson & Johnson shares is currently 2.51%.
To buy shares in Johnson & Johnson you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Johnson & Johnson are currently trading at $158.46, giving the company a market capitalisation of £298.98bn.
Here are the trading details for Johnson & Johnson:
Based on an overall assessment of its quality, value and momentum, Johnson & Johnson is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Johnson & Johnson are currently priced at $158.46. At that level they are trading at 4.87% discount to the analyst consensus target price of 0.00.
Analysts covering Johnson & Johnson currently have a consensus Earnings Per Share (EPS) forecast of 9 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Johnson & Johnson. Over the past six months, the relative strength of its shares against the market has been -5.72%. At the current price of $158.46, shares in Johnson & Johnson are trading at 5.53% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Johnson & Johnson PE ratio based on its reported earnings over the past 12 months is 21.67. The shares are currently trading at $158.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Johnson & Johnson's management team is headed by:
Here are the top five shareholders of Johnson & Johnson based on the size of their shareholding:
